Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial
Loading...
Date
2022-12-01
Authors
Lawrence, David S.
Tugume, Lillian
Mwandumba, Henry C.
Kanyama, Cecilia
Muzoora, Conrad
Nuwagira, Edwin
Niessen, Louis W.
Journal Title
Journal ISSN
Volume Title
Publisher
The Lancet Global Health
Abstract
HIV-associated cryptococcal meningitis is a leading cause of AIDS-related mortality. The AMBITION-cm trial showed that a regimen based on a single high dose of liposomal amphotericin B deoxycholate (AmBisome group) was non-inferior to the WHO-recommended treatment of seven daily doses of amphotericin B deoxycholate (control group) and was associated with fewer adverse events. We present a five-country cost-effectiveness analysis.
Description
Keywords
Citation
Lawrence, D. S., Muthoga, C., Meya, D. B., Tugume, L., Williams, D., Rajasingham, R., ... & Kufa, P. (2022). Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial. The Lancet Global Health, 10(12), e1845-e1854.